Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
Australia
Fiona Stanley Hospital, Murdoch, Perth Royal Prince Alfred Hospital, Camperdown, Sydney The Alfred Hospital, Melbourne, Victoria United Kingdom
Richmond Pharmacology, London